Price
CHART BY
Frequently asked questions
What is Sellas's market capitalization?
The market capitalization of Sellas is $2.67B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Sellas?
Sellas's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.212. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Sellas's stock?
Currently, 2 analysts cover Sellas's stock, with a consensus target price of $32.50. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Sellas?
Sellas's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$35.22M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Sellas?
Sellas has a free cash flow of -$28.42M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Sellas have, and what sector and industry does it belong to?
Sellas employs approximately 13 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Sellas's shares?
The free float of Sellas is 199.51M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.67B
- EPS (TTM)
- -$0.212
- Free Float
- 199.51M
- EBITDA (TTM)
- -$35.22M
- Free Cashflow (TTM)
- -$28.42M
Pricing
- 1D span
- $13.33$13.80
- 52W span
- $1.39$15.87
Analyst Ratings
The price target is $32.50 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
- Employees
- 13
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- SLS
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet